Tempus AI (NASDAQ:TEM) Downgraded by Wall Street Zen to Sell

Tempus AI (NASDAQ:TEM) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

A number of other analysts have also weighed in on the stock. HC Wainwright lowered their price objective on shares of Tempus AI from $98.00 to $89.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Morgan Stanley upped their price target on shares of Tempus AI from $80.00 to $85.00 and gave the stock an “overweight” rating in a research report on Monday, December 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tempus AI in a research note on Thursday, January 22nd. Mizuho assumed coverage on shares of Tempus AI in a report on Thursday, February 19th. They set an “outperform” rating and a $100.00 price objective on the stock. Finally, BTIG Research lowered their target price on Tempus AI from $105.00 to $90.00 and set a “buy” rating for the company in a report on Wednesday. Eight investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Tempus AI currently has a consensus rating of “Moderate Buy” and an average price target of $79.31.

Tempus AI Price Performance

Shares of TEM stock opened at $53.25 on Friday. Tempus AI has a twelve month low of $36.22 and a twelve month high of $104.32. The company has a current ratio of 3.13, a quick ratio of 3.12 and a debt-to-equity ratio of 2.52. The stock has a fifty day simple moving average of $61.34 and a two-hundred day simple moving average of $73.28. The stock has a market capitalization of $9.47 billion, a price-to-earnings ratio of -37.77 and a beta of 5.22.

Insiders Place Their Bets

In other news, EVP Andrew Polovin sold 10,949 shares of the company’s stock in a transaction on Friday, February 20th. The stock was sold at an average price of $60.31, for a total transaction of $660,334.19. Following the transaction, the executive vice president directly owned 126,918 shares of the company’s stock, valued at approximately $7,654,424.58. This represents a 7.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Erik Phelps sold 9,464 shares of the firm’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $59.43, for a total value of $562,445.52. Following the completion of the sale, the executive vice president directly owned 79,816 shares of the company’s stock, valued at $4,743,464.88. The trade was a 10.60% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 596,035 shares of company stock valued at $37,505,125. 26.27% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Tempus AI

Hedge funds and other institutional investors have recently modified their holdings of the stock. Royal Bank of Canada boosted its stake in Tempus AI by 201.2% in the 1st quarter. Royal Bank of Canada now owns 25,988 shares of the company’s stock worth $1,253,000 after purchasing an additional 17,359 shares in the last quarter. Rhumbline Advisers purchased a new position in shares of Tempus AI in the first quarter worth $116,000. Envestnet Asset Management Inc. lifted its stake in shares of Tempus AI by 2.6% during the second quarter. Envestnet Asset Management Inc. now owns 62,005 shares of the company’s stock worth $3,940,000 after buying an additional 1,558 shares during the period. Amalgamated Bank purchased a new stake in shares of Tempus AI during the second quarter valued at $394,000. Finally, Creative Financial Designs Inc. ADV purchased a new stake in shares of Tempus AI during the second quarter valued at $47,000. 24.22% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Beat-and-raise fundamentals — Tempus reported robust Q4 and full‑year 2025 results (strong revenue growth, narrower net loss, positive adjusted EBITDA progression) and issued 2026 guidance that targets revenue growth and a first full‑year adjusted EBITDA inflection, supporting a fundamental recovery case. Why Tempus AI (TEM) Is Down 7.5% After 2025 Results
• Positive Sentiment: Product & commercial catalysts — Launch of an HRD‑RNA oncology algorithm and a partnership with Median Technologies to expand lung cancer screening distribution broaden Tempus’s diagnostic pipeline and addressable market if adoption scales. Tempus AI Deepens Precision Oncology Role With New HRD And Lung Tools
• Positive Sentiment: Institutional support and rebound narrative — Several outlets highlight heavy institutional buying, improving unit economics and analyst upside scenarios, which could limit downside and set up a technical rebound if execution continues. Tempus AI Sold Off After a Beat—But the Rebound Case Is Building
• Neutral Sentiment: Investor event calendar — Management will present at the Morgan Stanley TMT conference (March 3); the fireside chat could provide additional color but is not a guaranteed catalyst. Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference
• Neutral Sentiment: Valuation updates — Some fair‑value and price‑target revisions trimmed upside modestly; analysts still show a range of bullish and cautious views, leaving the story sensitive to near‑term execution. How The Tempus AI (TEM) Investment Story Is Evolving With New Data And Valuation Views
• Negative Sentiment: Analyst downgrades and price‑target cuts — Recent analyst actions (including a notable downgrade reported 2/27 and several target cuts in the prior 24 hours) have intensified selling pressure and weakened sentiment despite the beat. Tempus AI (NASDAQ:TEM) Shares Down 7.4% After Analyst Downgrade
• Negative Sentiment: ESOP shelf registration and dilution risk — Tempus filed a US$343.38M ESOP‑related shelf registration; potential future share issuance tied to employee plans can pressure the stock if investors fear dilution. Why Tempus AI (TEM) Is Down 7.5% After 2025 Results
• Negative Sentiment: Execution, debt and market risk — High leverage, a volatile post‑IPO trading history, elevated beta and lingering execution/valuation concerns make the stock susceptible to outsized moves on negative headlines. Is It Time To Reassess Tempus AI (TEM) After Recent Share Price Weakness?

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.